Citigroup raises its price target on Neutral-rated DaVita DVA to $89 from $87 on on broader market valuation considerations following the company's integrated care ESRD opportunity.
Citigroup says, "We believe integrated care could theoretically boost DVA's earnings power by 10% but only once ALL U.S. dialysis patients are enrolled, a process that we doubt could be completed sooner than 2016 or 2017. DVA remains an "S&P stock" in our opinion, rated Neutral. We are raising our PT to $89, due entirely to an increase in broader market valuations (S&P500 +13% since out last update)."
DVA closed at $85.48 a share on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in